Altimmune, Inc.

Altimmune is a late clinical-stage biopharmaceutical company developing therapies to improve the lives of people living with serious liver diseases. Our lead program is a differentiated dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio, currently in development for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). #ClinicalResearch #LiverCare #BioResearch